Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®)

A clinical study on the efficacy and safety of follitropin alfa has been conducted. The aim of the study was to confirm the therapeutic equivalence between the follitropin alfa biosimilar (Primapur®) and the reference medication (Gonal-f®) in controlled induction of superovulation within the assiste...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Акушерство, гинекология и репродукция
المؤلفون الرئيسيون:	Z. B. Barakhoeva, L. A. Vovk, I. V. Zorina, N. Yu. Belousova, T. A. Teterina, S. A. Yakovenko, V. P. Apryshko, Yu. A. Fetisova, N. A. Marilova, E. G. Morozova, M. M. Ovchinnikova, M. A. Tishenko, Yu. V. Sherbatyuk, A. V. Kolotovkina, A. A. Miskun, G. V. Kasyanova, L. G. Sichinava, R. I. Shalinа, M. A. Polzikov
التنسيق:	مقال
اللغة:	الروسية
منشور في:	IRBIS LLC 2018-11-01
الموضوعات:	follitropin alfa recombinant follicle-stimulating hormone biosimilar in vitro fertilization assisted reproductive technologies
الوصول للمادة أونلاين:	https://www.gynecology.su/jour/article/view/506